A 62-year-old woman with unstable angina undergoes urgent percutaneous coronary intervention. She receives an intravenous antiplatelet agent and subsequently develops a platelet count of 78,000/μL. Her vital signs are BP 138/82, HR 94, RR 16, temperature 37.2°C, and SpO2 98% on room air. She denies bleeding or bruising. The drug blocks the final common pathway of platelet aggregation by inhibiting the glycoprotein IIb/IIIa receptor. Which agent was most likely administered?
- A)Aspirin
- B)Bivalirudin
- C)Clopidogrel
- D)Warfarin
- E)AbciximabGABARITO
Explicação
Abciximab is a monoclonal antibody fragment that inhibits the platelet GPIIb/IIIa receptor, preventing fibrinogen mediated platelet cross-linking. Because this receptor represents the final common pathway for aggregation, inhibition is potent and useful around... Ver explicação completa e trilha adaptativa →